Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NMRA Neumora Therapeutics	$1.62 -1.2%	$1.38	$0.61 ▼ $17.19	$265.59M	2.91	1.13 million shs	338,797 shs
STOK Stoke Therapeutics	$19.56 -0.6%	$13.31	$5.35 ▼ $19.91	$1.08B	1.15	867,662 shs	1.15 million shs
SYRE Spyre Therapeutics	$17.38 +3.6%	$16.16	$10.91 ▼ $40.26	$1.01B	2.82	524,325 shs	805,613 shs
UPB Upstream Bio	$17.63 -0.6%	$13.34	$5.14 ▼ $29.46	$956.35M	N/A	512,945 shs	289,080 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NMRA Neumora Therapeutics	-1.22%	-0.61%	-12.43%	+138.34%	-86.63%
STOK Stoke Therapeutics	-0.61%	+7.41%	+37.07%	+108.97%	+32.16%
SYRE Spyre Therapeutics	+3.58%	+2.54%	-2.41%	+15.79%	-34.59%
UPB Upstream Bio	-0.62%	-6.87%	+52.91%	+92.47%	+1,762,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
NMRA Neumora Therapeutics	2.3895 of 5 stars	3.1	3.0	0.0	1.4	2.5	0.6
STOK Stoke Therapeutics	4.5662 of 5 stars	4.6	1.0	4.8	2.6	0.8	1.3
SYRE Spyre Therapeutics	2.905 of 5 stars	3.6	2.0	0.0	2.6	2.5	0.6
UPB Upstream Bio	2.1217 of 5 stars	3.5	0.0	0.0	2.4	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NMRA Neumora Therapeutics	2.22	Hold	$7.14	340.92% Upside
STOK Stoke Therapeutics	3.22	Buy	$25.57	30.73% Upside
SYRE Spyre Therapeutics	3.29	Buy	$53.40	207.25% Upside
UPB Upstream Bio	3.00	Buy	$56.50	220.48% Upside

Current Analyst Ratings Breakdown

Latest NMRA, SYRE, UPB, and STOK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	STOK Stoke Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$28.00
8/13/2025	STOK Stoke Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00
8/13/2025	STOK Stoke Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $22.00
8/6/2025	SYRE Spyre Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$65.00
7/18/2025	STOK Stoke Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
7/16/2025	NMRA Neumora Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$4.00 ➝ $5.00
7/1/2025	STOK Stoke Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	$1.13 per share	N/A
STOK Stoke Therapeutics	$36.56M	29.32	N/A	N/A	$6.11 per share	3.20
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	$4.97 per share	N/A
UPB Upstream Bio	$2.37M	401.03	N/A	N/A	$7.58 per share	2.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NMRA Neumora Therapeutics	-$243.79M	-$1.57	N/A	N/A	N/A	N/A	-98.95%	-87.68%	11/11/2025 (Estimated)
STOK Stoke Therapeutics	-$88.98M	$0.85	23.01	N/A	N/A	26.25%	18.32%	15.48%	11/4/2025 (Estimated)
SYRE Spyre Therapeutics	-$208.02M	-$3.40	N/A	N/A	N/A	N/A	-71.30%	-38.69%	11/6/2025 (Estimated)
UPB Upstream Bio	-$62.81M	N/A	0.00	N/A	N/A	-3,836.58%	-35.90%	-26.26%	11/6/2025 (Estimated)

Latest NMRA, SYRE, UPB, and STOK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	STOK Stoke Therapeutics	-$0.57	-$0.40	+$0.17	-$0.40	$31.51 million	$13.82 million
8/6/2025	Q2 2025	NMRA Neumora Therapeutics	-$0.38	-$0.33	+$0.05	-$0.33	N/A	N/A
8/6/2025	Q2 2025	UPB Upstream Bio	-$0.61	-$0.74	-$0.13	-$0.74	$0.32 million	$0.94 million
8/5/2025	Q2 2025	SYRE Spyre Therapeutics	-$0.73	-$0.49	+$0.24	-$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A
UPB Upstream Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NMRA Neumora Therapeutics	0.11	10.54	10.54
STOK Stoke Therapeutics	N/A	6.98	6.98
SYRE Spyre Therapeutics	N/A	6.49	6.49
UPB Upstream Bio	N/A	38.27	38.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NMRA Neumora Therapeutics	47.65%
STOK Stoke Therapeutics	N/A
SYRE Spyre Therapeutics	80.39%
UPB Upstream Bio	N/A

Insider Ownership

Company	Insider Ownership
NMRA Neumora Therapeutics	26.80%
STOK Stoke Therapeutics	9.50%
SYRE Spyre Therapeutics	15.43%
UPB Upstream Bio	13.56%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NMRA Neumora Therapeutics	108	161.95 million	118.54 million	Optionable
STOK Stoke Therapeutics	100	54.80 million	49.59 million	Optionable
SYRE Spyre Therapeutics	73	60.40 million	51.08 million	Optionable
UPB Upstream Bio	38	53.91 million	46.60 million	N/A

NMRA, SYRE, UPB, and STOK Headlines

Recent News About These Companies

Upstream Bio (NASDAQ:UPB) Shares Down 4.8% - Here's What Happened

August 20 at 4:44 PM | marketbeat.com

Upstream Bio Initiates Phase 2 Clinical Trial for COPD Drug, Verekitug

August 20 at 4:58 AM | msn.com

Upstream Bio (NASDAQ:UPB) Sees Unusually-High Trading Volume - Here's Why

August 12, 2025 | marketbeat.com

Q3 EPS Estimates for Upstream Bio Cut by William Blair

August 9, 2025 | marketbeat.com

Upstream Bio Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

August 8, 2025 | finance.yahoo.com

Upstream Bio (UPB) Q2 R&D Soars 169%

August 6, 2025 | fool.com

Upstream Bio, Inc. reports Q2 results

August 6, 2025 | seekingalpha.com

Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress

August 6, 2025 | globenewswire.com

Upstream Bio (NASDAQ:UPB) Stock Price Up 8.1% - Still a Buy?

July 31, 2025 | marketbeat.com

Upstream Bio (UPB) Expected to Announce Quarterly Earnings on Tuesday

July 29, 2025 | marketbeat.com

Promising Outlook for Upstream Bio, Inc. as Verekitug Advances in Inflammatory Conditions

July 28, 2025 | tipranks.com

Positive Outlook for Upstream Bio, Inc. Driven by Promising Phase II Study of Verekitug in CRSwNP Treatment

July 28, 2025 | tipranks.com

Upstream Bio Inc. (UPB) Stock Price Today - WSJ

July 25, 2025 | wsj.com

Upstream Bio (NASDAQ:UPB) Trading Up 10% - Still a Buy?

July 25, 2025 | marketbeat.com

Upstream Bio begins phase 2 COPD trial for verekitug

July 10, 2025 | uk.investing.com

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic ...

July 8, 2025 | bakersfield.comB

Upstream Bio Initiates Phase 2 VENTURE Trial for Verekitug in Moderate-to-Severe COPD, Expanding Its Respiratory Portfolio

July 8, 2025 | quiverquant.comQ

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

July 8, 2025 | globenewswire.com

UPB Upstream Bio, Inc. - Seeking Alpha

June 28, 2025 | seekingalpha.com

Upstream Bio, Inc.’s Verekitug: A Promising Contender in the TSLPR Antibody Space

June 16, 2025 | tipranks.com

Upstream Bio Stock Gets A Boost As New Lung Inflammation Drug Shows Higher Potency

June 15, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMRA, SYRE, UPB, and STOK Company Descriptions

Neumora Therapeutics NASDAQ:NMRA

$1.62 -0.02 (-1.22%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.64 +0.02 (+1.23%)

As of 08/22/2025 07:57 PM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Stoke Therapeutics NASDAQ:STOK

$19.56 -0.12 (-0.61%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$19.47 -0.09 (-0.46%)

As of 08/22/2025 07:36 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Spyre Therapeutics NASDAQ:SYRE

$17.38 +0.60 (+3.58%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$17.30 -0.08 (-0.46%)

As of 08/22/2025 06:00 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Upstream Bio NASDAQ:UPB

$17.63 -0.11 (-0.62%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$17.62 -0.01 (-0.06%)

As of 08/22/2025 04:49 PM Eastern

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time